Targeting Signaling Excitability in Cervical and Pancreatic Cancer Cells Through Combined Inhibition of FAK and PI3K
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073040 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Chao-Cheng Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Sol Goldman Pancreatic Cancer Research Center, NIGMS NIH HHS.
Abstract (Originalsprache)
The Ras/PI3K/ERK signaling network is frequently mutated and overactivated in various human cancers. Focal adhesion kinase (FAK) is commonly overexpressed in several cancer types and has been implicated in treatment resistance mechanisms. A positive feedback loop between Ras, PI3K, the cytoskeleton, and FAK was previously shown to drive Ras signaling excitability. In this study, we investigated the effectiveness of targeting Ras signaling excitability by concurrently inhibiting FAK and PI3K in cervical and pancreatic cancer cells, which depend on activation Ras/PI3K signaling. We found that the combination of FAK and PI3K inhibitors synergistically suppressed the growth of cervical and pancreatic cancer cell lines through increased apoptosis and decreased mitosis. PI3K inhibitors alone caused only a transient suppression of downstream AKT activity and paradoxically increased FAK signaling in cancer cells. The addition of an FAK inhibitor effectively counteracted this PI3K-inhibitor-induced FAK activation. Furthermore, PI3K inhibitors were found to activate multiple receptor tyrosine kinases (RTKs), including insulin receptor, IGF-1R, EGFR, HER2, HER3, AXL, and EphA2. Taken together, our results suggest that FAK inhibition is necessary to counteract the compensatory RTK activation induced by PI3K inhibitors, thereby achieving more effective suppression of cancer cell growth. These findings highlight the therapeutic potential of combined FAK and PI3K inhibition in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
- Department of Cell Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
- Center for Cell Dynamics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
ORCID-Profile: Chao-Cheng Chen, Suyang Wang, Jr-Ming Yang, Chuan-Hsiang Huang
Förderung
- NCI NIH HHS
- Sol Goldman Pancreatic Cancer Research Center
- NIGMS NIH HHS
- Cervical Cancer SPORE
- NIH
Zitieren
APA
Chen, C. C., Wang, S., Yang, J. M., & Huang, C. H. (2025). Targeting Signaling Excitability in Cervical and Pancreatic Cancer Cells Through Combined Inhibition of FAK and PI3K. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073040
Vancouver
Chen CC, Wang S, Yang JM, Huang CH. Targeting Signaling Excitability in Cervical and Pancreatic Cancer Cells Through Combined Inhibition of FAK and PI3K. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073040
BibTeX
@article{Chen2025,
author = {Chen, Chao-Cheng and Wang, Suyang and Yang, Jr-Ming and Huang, Chuan-Hsiang},
title = {Targeting Signaling Excitability in Cervical and Pancreatic Cancer Cells Through Combined Inhibition of FAK and PI3K},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073040}
}
EUVIMED